{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:45:27Z","timestamp":1787957127661,"version":"build-2784847793"},"reference-count":37,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/17474086.2025.2523551","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T19:05:06Z","timestamp":1750705506000},"page":"585-593","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion?"],"prefix":"10.1080","volume":"18","author":[{"given":"Jean A.","family":"Yared","sequence":"first","affiliation":[{"name":"University of Maryland Baltimore School of Medicine","place":["Baltimore, MD, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Fromowitz","sequence":"additional","affiliation":[{"name":"University of Maryland Baltimore School of Medicine","place":["Baltimore, MD, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kocoglu","sequence":"additional","affiliation":[{"name":"University of Maryland Baltimore School of Medicine","place":["Baltimore, MD, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Hardy","sequence":"additional","affiliation":[{"name":"University of Maryland Baltimore School of Medicine","place":["Baltimore, MD, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[{"name":"University of Maryland Baltimore School of Medicine","place":["Baltimore, MD, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"University of Maryland Baltimore School of Medicine","place":["Baltimore, MD, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Cancer Facts & Figures. 2025. Published online 1930."},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24862"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0051"},{"key":"e_1_3_4_6_1","unstructured":"ASH Clinical Practice Guidelines. [cited 2025 Mar 14]. Available from: https:\/\/www.hematology.org\/education\/clinicians\/guidelines-and-quality-care\/clinical-practice-guidelines"},{"key":"e_1_3_4_7_1","unstructured":"Acute Lymphoblastic Leukemia Guidelines - Hematology.Org. [cited 2025 Mar 14]. Available from: https:\/\/www.hematology.org\/education\/clinicians\/guidelines-and-quality-care\/clinical-practice-guidelines\/acute-lymphoblastic-leukemia-guidelines"},{"issue":"9","key":"e_1_3_4_8_1","article-title":"Version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Acute Lymphoblastic Leukemia","year":"2021","unstructured":"Acute Lymphoblastic Leukemia. Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2021 [cited 2025 Mar 14];19(9). Available from: https:\/\/jnccn.org\/view\/journals\/jnccn\/19\/9\/article-p1079.xml","journal-title":"J Natl Compr Cancer Network"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023568"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.84"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009462"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003554"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144311"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03279"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000017"},{"key":"e_1_3_4_20_1","unstructured":"Frey. CART22-65s co-administered with huCART19 in\u2026 - Google scholar. [cited 2025 Mar 14]. Available from: https:\/\/scholar.google.com\/scholar_lookup?journal=Blood&title=CART22-65s%20co-administered%20with%20huCART19%20in%20adult%20patients%20with%20relapsed%20or%20refractory%20ALL&author=NV%20Frey&author=S%20Gill&author=WT%20Hwang&volume=138&issue=Suppl%201&publication_year=2021&"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826"},{"key":"e_1_3_4_22_1","unstructured":"DailyMed - AUCATZYL- obecabtagene autoleucel kit. [cited 2025 Mar 14]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=4fef6986-b988-45e4-8c20-b14f0ef1f538&audience=consumer"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00917"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181574"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00418-1"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","unstructured":"Roddie C. Obecabtagene autoleucel (obe-cel AUTO1) for relapsed\/refractory adult B-cell acute lymphoblastic leukemia (R\/R B-ALL): pooled analysis of the ongoing FELIX phase Ib\/II study. In: ASH; 2023 [cited 2025 Mar 27]. Available from: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper179454.html","DOI":"10.1182\/blood-2023-179454"},{"key":"e_1_3_4_28_1","unstructured":"Roddie C Sandhu KS Tholouli E et al. Obecabtagene autoleucel (OBE-CEL Auto1) for relapsed\/refractory adult B-cell acute lymphoblastic leukemia (R\/R B-ALL): pooled analysis of the ongoing felix phase IB\/II study."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406526"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.332"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6504"},{"key":"e_1_3_4_33_1","unstructured":"Research C for DE and. FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. FDA. Published online 2024 Nov 8 [cited 2025 Mar 14]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute"},{"key":"e_1_3_4_34_1","unstructured":"Autolus therapeutics announces acceptance of marketing authorization application (MAA) by the European medicines agency (EMA) for obecabtagene autoleucel (obe-cel) for patients with relapsed\/refractory (r\/r) adult B-Cell acute lymphoblastic leukemia (B-ALL) \u2013 1stOncologyTM. Cancer intelligence Service. 2024 Apr 2 [cited 2025 Mar 14]. Available from: https:\/\/www.1stoncology.com\/blog\/autolus-therapeutics-announces-acceptance-of-marketing-authorization-application-maa-by-the-european-medicines-agency-ema-for-obecabtagene-autoleucel-obe-cel-for-patients-with-relapsedrefractory-rr-a1\/"},{"key":"e_1_3_4_35_1","unstructured":"Autolus therapeutics announces acceptance of marketing authorization application (MAA) by the European medicines agency (EMA) for obecabtagene autoleucel (obe-cel) for patients with relapsed\/refractory (r\/r) adult B-cell acute lymphoblastic leukemia (B-ALL). |. [cited 2025 Mar 14]. Available from: https:\/\/autolus.gcs-web.com\/news-releases\/news-release-details\/autolus-therapeutics-announces-acceptance-marketing\/"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020023"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150609"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01436-0"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.027"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2025.2523551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T10:23:55Z","timestamp":1754043835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2025.2523551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/17474086.2025.2523551"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2025.2523551","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}